Clinical efficacy of the combined use of levofloxacin and different courses of isoniazid and rifampicin in the treatment of mild spinal tuberculosis
Abstract
Purpose: To investigate the clinical effectiveness of the combined use of levofloxacin and different courses of isoniazid and rifampicin in the treatment of mild spinal tuberculosis (TB). Methods: The clinic data of 100 patients with light spinal TB were retrospectively reviewed. A double-blind technique was used to divide the patients into 6-month treatment group (M6 group, n = 32), 12-month treatment group (M12 group, n = 34) and 18-month treatment group (M18 group, n = 34). All patients were given isoniazid and rifampicin, in combination with levofloxacin. The effects of the different treatment courses on mild spinal TB were determined. Results: There were significantly higher post-treatment levels of inflammatory factors in M6 group than in M12 and M18 groups (p < 0.001). Moreover, there were significantly higher Visual Analogue Scale (VAS) score and erythrocyte sedimentation rate (ESR), and larger focus size in M6 group than in M12 and M18 groups (p < 0.05). However, after treatment, M18 group had significantly higher total incidence of adverse reactions than M6 and M12 groups (p < 0.05). Conclusion: Compared with the short-course treatment, long-course treatment with isoniazid and rifampicin in combination with levofloxacin is more effective in reducing the levels of inflammatory factors and decreasing focus size in patients with mild spinal TB. However, patients given the 18-month treatment tend to develop more adverse reactions. Therefore, 12-month treatment with the…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.